ALKS
Drug Manufacturers - Specialty & Generic · Healthcare
Analyst
H.C. Wainwright
Equibles does not estimate personal net worth.
Douglas Sow is recorded as Analyst at H.C. Wainwright. Douglas Sow has spoken on 10 earnings calls and 1 other investor event across 7 companies, most recently for Viridian Therapeutics, Inc.\DE on November 4, 2026. Those appearances were for Alkermes plc. (ALKS), Crinetics Pharmaceuticals, Inc., Viridian Therapeutics, Inc.\DE (VRDN), Argenx SE (ARGX), Hansa Biopharma AB and 2 other companies. The companies whose calls Douglas Sow spoke on are classified in the Healthcare sector.
“I guess just maybe as a follow-up on that last one in terms of prescribers, I'm just curious, are you typically seeing prescribers sort of initially trialing patients, or have you had instances with clinicians who were perhaps familiar with the drug from a clinical trial experience or just, you know, excited about the…”
“Just on 7290 into MDD, I was just curious. It sounds like you are looking into the drug's effect on sort of some of the specific domains of the madras. I'm just curious, are you looking at things like SHAPS?”
“Maybe I would just be curious to hear from Sandrine, from her perspectives, from coming back from Anam, because at the conference, it was really striking how many of the podium presentations were focused on both seronegative as well as ocular.”
“I think you made the comment at the beginning of the call that you had become sort of more optimistic or, you know, sort of enthusiastic about the Avidel transaction in Lumarize.”
“Just quickly, in terms of the U.S. opportunity, Maria, you sort of touched on, you know, the fact that this is mostly a Medicare market.”
H.C. Wainwright
Analyst
Transcript header (unverified)
ALKS
Drug Manufacturers - Specialty & Generic · Healthcare
Crinetics Pharmaceuticals, Inc.
Biotechnology · Healthcare
ARGX
Biotechnology · Healthcare
Hansa Biopharma AB
Biotechnology · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
Interim Report January-June 2026 Conference Call
Hansa Biopharma AB
Crinetics Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Crinetics Pharmaceuticals, Inc.